March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)
March 9, 2017: UBS initiates Vertex Pharmaceuticals Inc with a Buy rating and a price target of $106. UBS is launching coverage of US Biotechnology with a positive outlook buoyed by (1) a better line-up of drug launches for 2017 (Biogen’s Spinraza for SMA; Regeneron’s Dupixent for atopic dermatitis, and Incyte’s Olumiant for rheumatoid arthritis), (Read More….)
GBT exploded into position #1 gaining 31% last week. Nomura initiated coverage of GBT with a Buy rating and a price target of $50. Let’s go ahead and book profits on Monday if you haven’t already. Remember folks, sell into strength and don’t wait for me to issue a sell signal before cashing out and (Read More….)
March 4, 2017: Sell Exact Sciences for a 55% win in 37 days. Congratulations if you were able to make money on the trade and always remember to sell your positions before you get the sell alert from me. I review more than 200 open stock positions over the weekend when I have time and (Read More….)
February 15, 2017: Lightpath Technologies reports Q2 EPS of $0.06 versus the $0.02 estimate. Revenue also beat coming in at $5.9 million versus the $5 million estimate.
December 22, 2016: Roth Capital initiates coverage of LightPath Technologies with a Buy rating, and a price target of $2.50. Roth Capital thinks LightPath is a business that (Read More….)
February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is being dragged down unfairly into the price-gouging muck by Marathon Pharmaceuticals.” Source: https://www.thestreet.com/story/14001431/1/defending
January 10, 2017: Baird reiterates a Buy rating on biotechnology firm Sarepta Therapeutics and set a price target of $102. Baird named Sarepta (Read More….)
February 14, 2017: JP Morgan making positive comments about Gilead Sciences, reiterates their Overweight rating. JP Morgan says that ahead of a presentation today at CROI (2/13-17, Seattle), GILD released the anticipated results from the Phase 2 trial evaluating its novel unboosted integrase inhibitor bictegravir (BIC) vs. ViiV’s dolutegravir (DTG) in treatment naive HIV patients (Read More….)
February 6, 2017: Mylan stock got my attention today because the stock climbed on the news that Mylan has to pay $96.5 million in settlement of the Provigil antitrust class action suit. The settlement covers allegations that Mylan delayed launching its generic version of Cephalon narcolepsy drug Provigil in exchange for payment from Cephalon. The (Read More….)
February 1, 2017: Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Health Canada approved Kevzara™ (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Kevzara (Read More….)
January 23, 2017: Maxim raised ADMA Biologics to a Buy rating. Maxim said ADMA Biologics announced that it will acquire Biotest’s 126,000 square foot immunoglobulin manufacturing facility (where RI-002 is manufactured) as well as two FDA-approved immunoglobulin assets (BIVIGAM and Nabi-HB). When the deal closes (April/May 2017), ADMA Biologics will become a fully integrated plasma (Read More….)
January 19, 2017: AbbVie announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This indication is approved under accelerated approval based on overall response rate (ORR), and (Read More….)
January 9, 2017: Huron Consulting Group formed a doji today, in oversold territory, on news it acquired Pope Woodhead & Associates. Huron Consulting Group says that it has expanded its life sciences strategy expertise with the acquisition of Pope Woodhead & Associates. The UK-based consulting firm provides market access capabilities to assist clients in developing (Read More….)
February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)
December 29, 2016: Sell Eli Lilly for an 8.8% gain in 12 trading days. Congratulations if you were able to make money on the trade.
December 16, 2016: Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with Type 1 diabetes. This is a successful completion of an (Read More….)
December 28, 2016: Tonix Pharmaceuticals is forming a wide J Hook pattern after having the FDA granted their PTSD drug TNX-102 a Breakthrough Therapy designation.
December 19, 2016: Tonix Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to TNX-102 SL for the treatment of posttraumatic stress disorder (Read More….)
Overnight Analyst Actions:
REGN Outperform Credit Suisse First Boston TECK Outperform Macquarie
TECK Buy MKM Partners
AMGN Neutral Credit Suisse First Boston
Overnight Headlines By Ticker:
AMGN Amgen Inc
12/20 08:21 Credit Suisse Cuts AMGN to Neutral from Outperform, price target: $180
12/19 (Read More….)
Editas Medicine has an explosive Twiggs Money Flow on the chart.
Editas Medicine is a risky biotechnology stock with no P/E.
The catalyst is none other than the Biotech Discovery of the Century. Yeah, that sounds like major hype and maybe somebody is drinking the Kool-Aid. Nevertheless, the chart looks pretty sweet with the (Read More….)